For the seventh consecutive year, Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry.
For the seventh consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry.
“We are very proud of this recognition,” said Roche CEO Severin Schwan. “As an innovator in healthcare, we consider sustainability as both a responsibility and a value driver. The three elements of sustainability — societal, environmental and economic – are completely integrated into our business practices and the cornerstone of how Roche does its business.”
Through a multifaceted sustainability strategy, spanning corporate governance, operations, and stakeholder collaboration, Roche has maintained its leadership position in the pharmaceuticals industry. Roche performed particularly well across several categories, including code of conduct and compliance, risk and crisis management, supply chain management, environmental policy and management, talent attraction and retention.
With more than 100 new partnerships across academia, research institutions, venture firms and biotech companies established last year, DJSI noted in particular Roche’s strong culture of collaboration, broad approach to innovation, and commitment to furthering access to healthcare. Initiatives included early detection and treatment programmes in Africa, South America, and Asia, and working with the Transnet foundation in South Africa to deliver local healthcare solutions to remote communities. Additionally, DJSI commended Roche’s commitment to people, with leadership and development programmes encouraging diversity, professional and personal development. A pillar of our culture, Roche is committed to sustainability as an integral part of the way we do business now and in the future.